低剂量IL-2可预防但无法治疗实验性抗髓过氧化物酶肾小球肾炎
在C57BL/6J小鼠抗MPO肾小球肾炎模型中,低剂量IL-2(25000国际单位/天)被动模型虽增加肾脏Treg、限制巨噬细胞招募及促炎表型,但未改善肾损伤;主动模型预防性治疗可增加脾Treg、减弱抗MPO特异性Th1/Th17反应并减轻肾损伤;已建立免疫时治疗反而增强效应T细胞反应并加重肾小球损伤。
要点
- 被动抗MPO肾炎中低剂量IL-2有抗炎免疫效应但未改善肾损伤。
- 主动抗MPO肾炎预防性低剂量IL-2可减轻结构和功能肾损伤。
- 已建立免疫时低剂量IL-2或IL-2/抗IL-2复合物加重肾小球肾炎。
核心结论
- 在实验性抗MPO肾小球肾炎中,低剂量IL-2治疗对细胞和体液免疫具有背景特异性效应,其在已建立自身免疫中促进T效应反应的潜力可能限制其在此病症中的效用。
研究设计与样本
- 使用C57BL/6J小鼠的抗MPO肾小球肾炎实验模型,采用被动和主动两种模型评估低剂量IL-2(25000国际单位/天)的疗效。
主要发现
- 被动转移抗MPO抗体诱导的肾炎中,低剂量IL-2增加肾脏内Treg数量、限制巨噬细胞招募并减少肾脏巨噬细胞促炎表型,但这些免疫学变化未转化为肾损伤改善。
- MPO免疫并用抗肾小球基底膜球蛋白触发的T细胞介导主动抗MPO肾炎中,预防性IL-2治疗增加脾Treg、减弱抗MPO特异性Th1/Th17反应并限制结构和功能肾损伤。
- 已建立自身免疫中,MPO免疫后12天起给予低剂量IL-2的小鼠脾Treg扩增,但效应T细胞反应也增强且肾小球损伤加重。
- 在已建立抗MPO自身免疫的小鼠中,IL-2/抗IL-2免疫复合物治疗增加Treg频率,但矛盾性地放大抗MPO T细胞效应反应并加重肾小球肾炎。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出低剂量IL-2在AAV中的治疗潜力仍不明确,需进一步研究其在实验性AAV模型中的免疫调节作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is a major cause of glomerulonephritis (GN) and kidney failure and current therapies are often limited by significant toxicity and limitations. Regulatory T cells (Tregs) play a crucial role in maintaining immune tolerance, and their dysfunction has been implicated in AAV pathogenesis. Low dose interleukin-2 (IL-2) has emerged as a promising strategy to selectively expand Tregs and restore immune balance in several autoimmune diseases. However, low dose IL-2's therapeutic potential in AAV remains unclear, warranting further investigation into its immunoregulatory effects in experimental AAV models. METHODS: We tested the therapeutic efficacy of low dose IL-2 therapy (25 000 international units/day) in an experimental murine model of AAV, specifically anti-myeloperoxidase (MPO) GN, using C57BL/6J mice. Both passive and active models of anti-MPO GN were used to assess IL-2's effects across different disease settings. RESULTS: In GN induced by passive transfer of anti-MPO antibodies, low dose IL-2 increased intrarenal Treg numbers, limited macrophage recruitment, and reduced macrophage pro-inflammatory phenotype in kidneys, demonstrating anti-inflammatory effects on innate immunity. However, these immunological changes did not translate into improvement in kidney injury. In T-cell mediated active anti-MPO GN induced by MPO immunization and triggered by anti-glomerular basement membrane globulin, preventative IL-2 therapy increased splenic Tregs, attenuated anti-MPO-specific Th1/Th17 responses and limited structural and functional kidney injury. In established autoimmunity, mice treated with low dose IL-2 from 12 days after MPO immunization also expanded splenic Tregs. However, effector T-cell responses were also enhanced and glomerular injury was increased. To more specifically target Tregs and minimize low dose IL-2's potential to promote effector leukocytes, we administered IL-2 conjugated to an anti-IL-2 monoclonal antibody (IL-2/anti-IL-2 immune complex). Although IL-2/anti-IL-2 treatment increased Treg frequency in mice with established anti-MPO autoimmunity, it also paradoxically amplified anti-MPO T-cell effector responses and worsened glomerulonephritis. CONCLUSION: In experimental anti-MPO GN, low dose IL-2 therapy has context specific effects on cellular and humoral immunity, and the potential for it to promote T effector responses in established autoimmunity may limit its utility in this condition.
引用
- Dick J, Nagai K, Koo Yuk Cheong D, et al. Low dose IL-2 administration prevents but fails to treat experimental autoimmune anti-myeloperoxidase glomerulonephritis. Nephrol Dial Transplant. 2026. PMID: 40880081. doi:10.1093/ndt/gfaf178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。